Home » Stocks » IMVT

Immunovant, Inc. (IMVT)

Stock Price: $44.02 USD -0.49 (-1.10%)
Updated Jan 15, 2021 1:06 PM EST - Market open
Market Cap 4.36B
Revenue (ttm) n/a
Net Income (ttm) -79.34M
Shares Out 84.35M
EPS (ttm) -1.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $44.02
Previous Close $44.51
Change ($) -0.49
Change (%) -1.10%
Day's Open 44.02
Day's Range 42.47 - 44.48
Day's Volume 94,101
52-Week Range 8.36 - 52.71

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 1 day ago

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on monoclonal antibody therapeutic development for autoimmune diseases. Immunovant has a one product pipeline (IMVT-1401)...

GlobeNewsWire - 2 days ago

NEW YORK, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today ...

InvestorPlace - 3 weeks ago

There has been plenty of completed SPAC merger news in 2020 as more companies use it to go public and we're looking at the top performers. The post Completed SPAC Mergers 2020: 10 Top Performi...

Other stocks mentioned: AHCO, BWMX, DKNG, IRDM, LPRO, MP, QS, RPAY, SBE
GlobeNewsWire - 2 months ago

Company Ended the Quarter With Cash of Approximately $444 Million Company Ended the Quarter With Cash of Approximately $444 Million

PRNewsWire - 2 months ago

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiducia...

InvestorPlace - 3 months ago

In October, ther may be price pullbacks in shares of SPAC IPOs, offering long-term investors better entry points. The post 7 of the Most Interesting New SPACs to Take a Chance On appeared firs...

Other stocks mentioned: AHCO, DKNG, IPOB, RPAY, SPCE, WKHS
GlobeNewsWire - 4 months ago

NEW YORK, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune disease...

Investors Business Daily - 4 months ago

Hot biotech stock Immunovant on Wednesday priced its secondary offering of 5.27 million shares at $33 per share, as IMVT stock trades near record highs after a rival attracted a big suitor. Th...

GlobeNewsWire - 4 months ago

NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced the pricing of its underwritten public offering of 5,270,093 shares of its common stock at a pric...

Zacks Investment Research - 4 months ago

Immunovant's (IMVT) myasthenia gravis candidate, IMVT-1401, meets endpoints in a mid-stage study.

Business Wire - 4 months ago

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) OmniAb® partner Immunovant, Inc. (NASDAQ: IMVT) announced positive topline results from ASCEND MG, a Phase 2a stu...

GlobeNewsWire - 4 months ago

Company to Host Conference Call on August 25, 2020 at 8:30am EDT Company to Host Conference Call on August 25, 2020 at 8:30am EDT

GlobeNewsWire - 4 months ago

Dr. Elliott previously served as Vice President of Immunology Scientific Innovation at J&J and has led the clinical development of multiple blockbuster immunology products Dr. Elliott previous...

Benzinga - 4 months ago

Immunovant Inc (NASDAQ: IMVT) shares were ripping higher Wednesday in a sympathy move.

GlobeNewsWire - 5 months ago

NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases...

The Motley Fool - 5 months ago

Forget traditional IPOs! This blank check vehicle is proving to be an effective tool for biotech companies to raise capital.

Other stocks mentioned: PHGE, TXAC
GlobeNewsWire - 6 months ago

NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases...

Zacks Investment Research - 7 months ago

Immunovant (IMVT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 7 months ago

As of late, it has definitely been a great time to be an investor of Immunovant

GlobeNewsWire - 8 months ago

NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases,...

GlobeNewsWire - 8 months ago

NEW YORK, April 16, 2020 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune disease...

Zacks Investment Research - 8 months ago

Immunovant (IMVT) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

About IMVT

Immunovant, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York.... [Read more...]

Industry
Biotechnology
CEO
Dr. Peter Salzmann M.B.A., M.D.
Employees
42
Stock Exchange
NASDAQ
Ticker Symbol
IMVT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for Immunovant stock is "Strong Buy." The 12-month stock price forecast is 58.27, which is an increase of 32.37% from the latest price.

Price Target
$58.27
(32.37% upside)
Analyst Consensus: Strong Buy